About the symposium - Illustration

About the Symposium

The 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will take place as an in-person event at the CCIB in Barcelona in October 2024.

ENA 2024 stands as the drug development and translational research meeting, giving the spotlight to preclinical and phase I studies, ensuring in-depth scientific discussions on the latest developments in targets and drugs.

Attracting an international audience of academics, scientists and pharmaceutical industry leaders, this event enables discussions on the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

Reasons to participate

Participate - icon

ENA is at the
forefront of cancer
drug development

Participate - icon

Presentation of
new data

Participate - icon

with world
leading experts

Participate - icon

influencing future
clinical cancer
research to improve
survival and quality

If you have any question or need help, feel free to contact with our team

Key dates

Don’t want to miss any important key dates for ENA?

Plan ahead and add all the key dates for the conference into your diary.

Ensuring you don’t miss out on any deadlines.

Add to calendar

1 April
Abstract submission opens
29 May
Early rate registration
26 June
Abstract submission closes
4 September
Regular rate registration closes
18 September
Late breaking abstract submission opens
25 September
Late breaking abstract submission closes
9 October
Late rate registration closes

Our speakers

With a truly wide ranging scientific programme, the ENA 2024 Symposium brings together over 80 top experts in all fields of drug development and translational research from Europe and around the world.

Elizabeth De Vries, Chair, ENA 2024
Elisabeth de Vries
Chair ENA 2024
Timothy Yap, Co-Chair (AACR)
Timothy Yap
Co-Chair of AACR
Tim Greten, Co-Chair (NCI)
Tim Greten
Co-Chair of NCI
EORTC logo
National Cancer Institute - Logo
AACR - Logo